Coagulation Biomarker Reference Intervals in Healthy Pregnant Chinese Women
This study establishes trimester-specific reference intervals for four key coagulation biomarkers: thrombin-antithrombin complexes (TAT), prothrombin fragment 1+2 (PIC), thrombomodulin (TM), and tissue plasminogen activator inhibitor (tPAI-C). These intervals were determined in a cohort of healthy pregnant women in China. The research also explores the clinical associations of these biomarkers throughout the different trimesters of pregnancy. Understanding these normal ranges is crucial for accurately interpreting coagulation status in pregnant individuals. Deviations from these established intervals could potentially indicate underlying hemostatic abnormalities. The findings aim to provide a valuable resource for clinicians and researchers monitoring pregnancy-related coagulation changes. This information can aid in the early detection and management of potential complications. The study focuses on ensuring that reference values are tailored to the physiological changes occurring during pregnancy. By defining these specific intervals, the research contributes to improved diagnostic accuracy for coagulation disorders in this population.
Establishing precise, trimester-specific reference intervals for coagulation biomarkers during pregnancy is essential for distinguishing normal physiological adaptations from pathological conditions. This research addresses a critical need for culturally and ethnically relevant data, moving beyond generalized international standards. By providing these benchmarks for TAT, PIC, TM, and tPAI-C in healthy Chinese pregnant women, the study enhances diagnostic precision. This improved accuracy can mitigate risks associated with misinterpreting coagulation test results, potentially preventing unnecessary interventions or delayed treatment for emergent hemostatic issues. The long-term implication is a more nuanced understanding of maternal health, contributing to better obstetric care and potentially reducing adverse pregnancy outcomes by enabling earlier, more targeted clinical responses.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.